MX2022010513A - Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. - Google Patents
Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.Info
- Publication number
- MX2022010513A MX2022010513A MX2022010513A MX2022010513A MX2022010513A MX 2022010513 A MX2022010513 A MX 2022010513A MX 2022010513 A MX2022010513 A MX 2022010513A MX 2022010513 A MX2022010513 A MX 2022010513A MX 2022010513 A MX2022010513 A MX 2022010513A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- multiple sclerosis
- bruton
- inhibitor
- progressive multiple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
En la presente se proporcionan métodos para tratar esclerosis múltiple progresiva primaria (PPMS) en un sujeto que lo necesita, al administrar al sujeto alrededor de 200 mg de fenebrutinib dos veces por día, o una cantidad equivalente de una sal de este farmacéuticamente aceptable.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982872P | 2020-02-28 | 2020-02-28 | |
| US202063051756P | 2020-07-14 | 2020-07-14 | |
| PCT/US2021/019502 WO2021173740A1 (en) | 2020-02-28 | 2021-02-25 | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010513A true MX2022010513A (es) | 2022-09-21 |
Family
ID=74885089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010513A MX2022010513A (es) | 2020-02-28 | 2021-02-25 | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230091561A1 (es) |
| EP (1) | EP4110339A1 (es) |
| JP (2) | JP2023515528A (es) |
| KR (1) | KR20220148826A (es) |
| CN (1) | CN115175682A (es) |
| AU (1) | AU2021227674A1 (es) |
| BR (1) | BR112022017102A2 (es) |
| CA (1) | CA3170685A1 (es) |
| CL (1) | CL2022002317A1 (es) |
| IL (1) | IL295476A (es) |
| MX (1) | MX2022010513A (es) |
| TW (1) | TWI899163B (es) |
| WO (1) | WO2021173740A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI907406B (zh) | 2020-04-03 | 2025-12-11 | 美商建南德克公司 | 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法 |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| JP2018529747A (ja) * | 2015-10-06 | 2018-10-11 | ジェネンテック, インコーポレイテッド | 多発性硬化症を治療するための方法 |
| PL4049660T3 (pl) | 2016-02-29 | 2025-06-09 | F. Hoffmann-La Roche Ag | Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona |
| IL316573A (en) * | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| MX2021000094A (es) * | 2018-07-20 | 2021-03-25 | Merck Patent Gmbh | Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. |
| TWI907406B (zh) * | 2020-04-03 | 2025-12-11 | 美商建南德克公司 | 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法 |
-
2021
- 2021-02-25 TW TW110106714A patent/TWI899163B/zh active
- 2021-02-25 AU AU2021227674A patent/AU2021227674A1/en active Pending
- 2021-02-25 IL IL295476A patent/IL295476A/en unknown
- 2021-02-25 US US17/905,121 patent/US20230091561A1/en active Pending
- 2021-02-25 BR BR112022017102A patent/BR112022017102A2/pt unknown
- 2021-02-25 CN CN202180017387.XA patent/CN115175682A/zh active Pending
- 2021-02-25 KR KR1020227030440A patent/KR20220148826A/ko active Pending
- 2021-02-25 WO PCT/US2021/019502 patent/WO2021173740A1/en not_active Ceased
- 2021-02-25 MX MX2022010513A patent/MX2022010513A/es unknown
- 2021-02-25 EP EP21712677.0A patent/EP4110339A1/en active Pending
- 2021-02-25 JP JP2022550934A patent/JP2023515528A/ja not_active Withdrawn
- 2021-02-25 CA CA3170685A patent/CA3170685A1/en active Pending
-
2022
- 2022-08-24 CL CL2022002317A patent/CL2022002317A1/es unknown
-
2026
- 2026-01-07 JP JP2026001186A patent/JP2026082835A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL295476A (en) | 2022-10-01 |
| US20230091561A1 (en) | 2023-03-23 |
| WO2021173740A1 (en) | 2021-09-02 |
| JP2026082835A (ja) | 2026-05-19 |
| CA3170685A1 (en) | 2021-09-02 |
| AU2021227674A1 (en) | 2022-07-21 |
| CL2022002317A1 (es) | 2023-03-03 |
| EP4110339A1 (en) | 2023-01-04 |
| TWI899163B (zh) | 2025-10-01 |
| KR20220148826A (ko) | 2022-11-07 |
| JP2023515528A (ja) | 2023-04-13 |
| TW202146022A (zh) | 2021-12-16 |
| BR112022017102A2 (pt) | 2022-11-16 |
| CN115175682A (zh) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| ZA202306172B (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MX2025005489A (es) | Uso de lumateperona para el tratamiento del trastorno bipolar ii | |
| MX2022013647A (es) | Imidazopiridazinas como moduladores de il-17. | |
| MX2023002323A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| MX2021012705A (es) | Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa. | |
| MX2024014626A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton | |
| MX2024003772A (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| MX2024015988A (es) | Inhibidores terapeuticos de la tirosina cinasa para la esclerosis multiple y la miastenia grave | |
| EP4520398A3 (en) | Treatment of prostate cancer | |
| MX2024003770A (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| MY199779A (en) | Pyrrolopyrimidine compound and use thereof | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2024011249A (es) | Dosificacion no lineal de mirdametinib. | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| CL2022002317A1 (es) | Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. | |
| WO2021242844A8 (en) | Grk2 inhibitors and uses thereof | |
| PH12021550741A1 (en) | Vibegron for the treatment of overactive bladder symptoms | |
| PH12021551276A1 (en) | Combination therapy for the treatment of cancer | |
| PH12021551975A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2025014275A (es) | Derivado de pirrolopirimidina y uso del mismo en medicina | |
| WO2022177968A8 (en) | Therapeutic methods | |
| MX2023002422A (es) | Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. |